

### Remarks


Claims 1-4, 6-18, 20, 22, 24-27, 29-51 and 54-59 are pending in the application. Claim 1 is currently amended. No new matter has been introduced by virtue of the amendments made herein. Accordingly, applicants respectfully request their entry for the purposes of appeal. In view of the amendments made herein and the remarks below, applicants respectfully request reconsideration and withdrawal of the rejection set forth in the February 22, 2006 Office Action.

#### Rejection under 35 USC § 112, Second Paragraph


The Examiner rejected claim 1 and its dependant claims 35 USC § 112, second paragraph, as allegedly being indefinite because the recitation in claim 1 of "A" as "CH<sub>2</sub>" in formula I is unclear.

In an earlier amendment, applicants' attempted to point out that when "B" is absent (as defined in claim 1 in formula I), there is no valency problem with A when A = CH<sub>2</sub> because, in this instance, A is only bonded to G and the aromatic ring containing Y and Z.

However, in the interests of facilitating prosecution, applicants have amended claim 1 to remove any alleged ambiguity. As currently amended claim 1 now stands, there is an optional bond between A and B that exist only when B is methylene or ethylene (i.e. not hydrogen). For example, one embodiment of formula I when B is methylene and A is CH is 6-Methoxy-1-methyl-7-(6-phenyl-1-oxa-7-aza-spiro[4.5]dec-3-yl)-3,4-dihydro-1H-quinolin-2-one (See page 12 of specification, in preferred compound list):



Further, one embodiment when B is hydrogen and A is CH<sub>2</sub> is 7-[(1-Dimethylaminoacetyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-1-methyl-3,4-dihydro-1H-quinolin-2-one (See bottom of page 10 of the specification),




Accordingly, applicants respectfully submit that in view of the amendment made to claim 1 herein, and the remarks above, the pending claims are patentable under 35 USC § 112, second paragraph, and respectfully request that the Examiner to withdraw the rejection.

In view of the amendments set forth herein and remarks above, applicants respectfully submit that the pending claims are fully allowable, and solicit the issuance of a notice to such effect. If a telephone interview is deemed to be helpful to expedite the prosecution of the subject application, the Examiner is invited to contact applicants' undersigned attorney at the telephone number provided.

The Commissioner is hereby authorized to charge any fees required under 37 C.F.R. §§1.16 and 1.17 or to credit any overpayment to Deposit Account No. 16-1445.

Date: 4/4/06

  
\_\_\_\_\_  
Jason G. Tebbutt  
Attorney for Applicant(s)  
Reg. No. 55,671

Jolene Appleman  
Attorney for Applicant(s)  
Reg. No. 35,428

Pfizer Inc  
Patent Department  
150 East 42nd Street – 5<sup>th</sup> Floor  
New York, NY 10017-5755  
(212) 733-4827